| Drug Name |
Sunitinib malate |
| Drug ID |
BADD_D02101 |
| Description |
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. |
| Indications and Usage |
For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. |
| Marketing Status |
Prescription |
| ATC Code |
L01EX01 |
| DrugBank ID |
DB01268
|
| KEGG ID |
D06402
|
| MeSH ID |
D000077210
|
| PubChem ID |
6456015
|
| TTD Drug ID |
D0R0MW
|
| NDC Product Code |
0093-8224; 0093-8199; 16714-679; 63539-019; 16714-677; 16436-0091; 0069-0550; 54893-0081; 63539-017; 16714-678; 0378-6679; 0093-8229; 63304-094; 53183-4012; 76302-007; 68724-1234; 0069-0830; 0378-6678; 63304-092; 0069-0770; 63304-091; 68554-0078; 0069-0980; 0378-6681; 0378-6680; 63304-093; 16714-676; 0093-8231; 53296-0091 |
| Synonyms |
Sunitinib | 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide | Sunitinib Malate | Sutent | SU 11248 | SU011248 | SU 011248 | SU-011248 | SU11248 | SU-11248 |
